Membrane-bound CRPs such as CD55 (DAF) and CD59 (MSK21) are known to inhibit complement activity and are often upregulated in cancer (29, 30), with some prognostic capacity in HER2+ BC patients (42–44). This evidence concerns the gene CD59 and cancer.